8k

Left this out looking at a new boat!
20-Jan-2015
Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure.
On January 15, 2015 Unilife Corporation ("Unilife") entered into a definitive global strategic agreement with AbbVie Inc. ("AbbVie") for the customization and supply of its injectable drug delivery systems for use with AbbVie's drug portfolio.
Unilife has been selected by AbbVie as a preferred partner for the customization and supply of innovative, differentiated drug delivery systems. AbbVie will pay $5 million for the exclusive right to form and enter into a mutually-agreeable development and supply agreement with Unilife to include exclusive access to the Unifill Finesse� prefilled syringe and the LISA� reusable auto-injector for target therapies within AbbVie's drug portfolio for the treatment of auto-immune diseases, as well as associated exclusivity fees. The target therapies and conditions for which these systems will be used are confidential under the terms of the agreement.
About the Unifill Finesse�
The Unifill Finesse is a product configuration from Unilife's proprietary platform of ready-to-fill (prefilled) syringes with integrated, automatic needle retraction. Designed for integration with standard filling and packaging lines, it utilizes a standard plunger and plunger rod.
About the LISA Reusable Auto-Injector
The LISA reusable auto-injector is an automated and highly customizable product that can be used by a patient to perform hundreds of injections. Patients can control the speed of dose delivery to help minimize pain or discomfort during an injection. It allows for the removal of a used Unifill syringe with a retracted needle for safe, compact and convenient disposal. Other features include a single activation button, LED indicators and a push-on skin sensor to minimize potential drug wastage. Customization options include Bluetooth, Wi-Fi or 3G connectivity. RRM